Reconsideration of Interactions Between Direct Oral Anticoagulants and Calcineurin Inhibitors
Abstract
No abstract No abstract
1. Steffel J, Verhamme P, Potpara TS, et al. The 2018 european heart rhythm association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39(16):1330-93.
2. De Jonge H, De Loor H, Verbeke K, Vanrenterghem Y, Kuypers D. In vivo CYP3A activity is significantly lower in cyclosporine‐treated as compared with tacrolimus‐treated renal allograft recipients. Clin Pharmacol Ther 2011;90(3):414-22.
3. Lemahieu W, Maes B, Verbeke K, Vanrenterghem Y. CYP3A4 and P‐glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant 2004;4(9):1514-22.
4. Lam E, Bashir B, Chaballa M, Kraft WK. Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy. Expert Rev Clin Pharmacol 2019;12(8):781-90.
5. Alsheikh R, Alfayez OM, Al Yami MS. Insights from practice with use of direct oral anticoagulants in transplantation. Prog Transplant 2018;28(4):380-5.
6. Vanhove T, Spriet I, Annaert P, et al. Effect of the direct oral anticoagulants rivaroxaban and apixaban on the disposition of calcineurin inhibitors in transplant recipients. Ther Drug Monit 2017;39(1):77-82.
2. De Jonge H, De Loor H, Verbeke K, Vanrenterghem Y, Kuypers D. In vivo CYP3A activity is significantly lower in cyclosporine‐treated as compared with tacrolimus‐treated renal allograft recipients. Clin Pharmacol Ther 2011;90(3):414-22.
3. Lemahieu W, Maes B, Verbeke K, Vanrenterghem Y. CYP3A4 and P‐glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant 2004;4(9):1514-22.
4. Lam E, Bashir B, Chaballa M, Kraft WK. Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy. Expert Rev Clin Pharmacol 2019;12(8):781-90.
5. Alsheikh R, Alfayez OM, Al Yami MS. Insights from practice with use of direct oral anticoagulants in transplantation. Prog Transplant 2018;28(4):380-5.
6. Vanhove T, Spriet I, Annaert P, et al. Effect of the direct oral anticoagulants rivaroxaban and apixaban on the disposition of calcineurin inhibitors in transplant recipients. Ther Drug Monit 2017;39(1):77-82.
| Files | ||
| Issue | Vol 8, No 2 (Spring 2020) | |
| Section | Letter to the Editor | |
| DOI | https://doi.org/10.18502/jpc.v8i2.3834 | |
| Keywords | ||
| No Keywords | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Labbani-Motlagh Z, Dashti-Khavidaki S. Reconsideration of Interactions Between Direct Oral Anticoagulants and Calcineurin Inhibitors. J Pharm Care. 2020;8(2):88-89.
